– Presentation of cardiac and pulmonary function data from the ongoing PULSAR Phase 2 trial receives AHA’s “Cardiopulmonary Best Abstract” Award – – AHA sessions to include data from the ongoing SPECTRA Phase 2 trial – – Acceleron to host […]
Tag: Acceleron
Acceleron Announces Second Quarter 2020 REBLOZYL® Net Sales
– Acceleron expects to report approximately $11.1 million in royalty revenue for Q2 2020 from approximately $55.0 million in net U.S. sales of REBLOZYL® (luspatercept-aamt) as reported by Bristol Myers Squibb – – Acceleron will report its full second quarter 2020 […]
Acceleron Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that it intends to offer and sell, subject to market and […]
Acceleron Announces Publication in Science Translational Medicine Describing the Underlying Biology Behind Sotatercept’s Potential as a Novel Therapy in Pulmonary Arterial Hypertension
Preclinical research of murine version of sotatercept reveals significant role of key TGF-beta superfamily proteins, including activin and growth differentiation factor ligands, in pulmonary vascular disease; points to therapeutic strategy in pulmonary arterial hypertension (PAH) CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. […]
Acceleron Receives FDA Breakthrough Therapy Designation for Sotatercept in Pulmonary Arterial Hypertension
Sotatercept granted first FDA Breakthrough Therapy designation in pulmonary arterial hypertension since the Agency established the designation in 2012 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics […]
Acceleron Reports Fourth Quarter and Full Year 2019 Operating and Financial Results
– REBLOZYL® (luspatercept-aamt), a first-in-class erythroid maturation agent, was approved by the U.S. FDA for the treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell transfusions; FDA review of the sBLA for the lower-risk myelodysplastic syndromes indication […]
Recent
BrioHealth Solutions Begins Patient Enrollment in INNOVATE Trial of BrioVAD® System for Advanced Heart Failure
Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies
Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data
Popular
- No commented posts yet